Olanzapine in long-term treatment for bipolar disorder.

@article{Cipriani2009OlanzapineIL,
  title={Olanzapine in long-term treatment for bipolar disorder.},
  author={Andrea Cipriani and Jennifer M. Rendell and John R. Geddes},
  journal={The Cochrane database of systematic reviews},
  year={2009},
  volume={1},
  pages={
          CD004367
        }
}
BACKGROUND Many patients with bipolar disorder require long-term treatment to prevent recurrence. Antipsychotic drugs are often used to treat acute manic episodes. It is important to clarify whether olanzapine could have a role in long-term prevention of manic and depressive relapses. OBJECTIVES To assess the effects of olanzapine, as monotherapy or adjunctive treatment, in preventing manic, depressive and mixed episodes in patients with bipolar affective disorder. SEARCH STRATEGY We… 

Tables from this paper

Olanzapine in the long-term treatment of bipolar disorder: A systematic review and meta-analysis
TLDR
It is concluded that olanZapine may prevent further manic episodes only in patients who have responded to olanzapine in an acute manic or mixed episode and who have not previously had a satisfactory response to lithium or valproate.
Tiagabine in the maintenance treatment of bipolar disorder.
TLDR
The efficacy and acceptability of tiagabine were considered in terms of mood symptoms, mortality, general health, social functioning, adverse effects and overall acceptability to participants, and there is an insufficient methodologically rigorous evidence base to draw any conclusions regarding the use of tiabine in the maintenance treatment of bipolar disorder.
Efficacy and safety of lamotrigine in the treatment of bipolar disorder across the lifespan: a systematic review
TLDR
On the balance of efficacy and tolerability, LTG might be considered a first-line drug for BD, except for acute manic episodes or where rapid symptom control is required, but in terms of efficacy alone, the evidence favours other medications.
Aripiprazole monotherapy in the treatment of bipolar disorder: a meta-analysis.
Emerging treatments in the management of bipolar disorder – focus on risperidone long acting injection
TLDR
In this review, the aspects of pharmacology, pharmacokinetics, metabolism, safety and tolerability, and clinical trials focusing on the efficacy of RLAI in bipolar disorder are considered.
Maintaining mood stability in bipolar disorder: a clinical perspective on pharmacotherapy
TLDR
This review primarily included studies that were randomised, placebo-controlled, blinded, non-enriched and of sufficient duration to be regarded as maintenance therapy and their impact in determining treatment decisions was moderated accordingly.
Bipolar disorders: a review.
TLDR
Patients and their support systems should be educated about mood relapse, suicidal ideation, and the effectiveness of early intervention to reduce complications.
The Cost of Relapse for Patients with a Manic/Mixed Episode of Bipolar Disorder in the EMBLEM Study
TLDR
The findings confirm the significant economic impact of relapse in BD patients after an acute manic or mixed episode, even when considering direct costs only, which were dominated by inpatient stay.
Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder.
TLDR
The efficacy of valproate continuation and maintenance treatment was determined in preventing or attenuating manic, depressive and mixed episodes of bipolar disorder in patients with rapid cycling disorder and in improving patients' general health and social functioning.
...
1
2
3
4
...

References

SHOWING 1-10 OF 51 REFERENCES
Olanzapine alone or in combination for acute mania.
TLDR
Olanzapine is an effective treatment for mania and may be more efficacious than divalproex, though leads to more weight gain.
New treatments for bipolar disorder: the role of atypical neuroleptic agents.
  • S. Ghaemi
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 2000
TLDR
It seems unlikely that these agents will prove to be primary mood stabilizers in their own right in patients with bipolar disorder, but they serve an important role as adjunctive treatments along with standard mood stabilizer in the rational polypharmacy of bipolar disorder.
Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials.
TLDR
Lithium is effective in the prevention of suicide, deliberate self-harm, and death from all causes in patients with mood disorders, according to the Cochrane Collaboration.
Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial.
TLDR
It is suggested that olanzapine was significantly more effective than lithium in preventing manic and mixed episode relapse/recurrence in patients acutely stabilized with olanZapine and lithium co-treatment.
Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine.
TLDR
Compared to placebo, olanzapine delays relapse into subsequent mood episodes in bipolar I disorder patients who responded to open-label acute treatment with olanZapine for a manic or mixed episode.
Carbamazepine and valproate in the maintenance treatment of bipolar disorder.
TLDR
Although carbamazepine and valproate have been less well studied in maintenance treatment than lithium, each agent appears to have efficacy in this phase of illness management and combination therapy may provide better long-term prevention of illness relapse and recurrence.
Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone
TLDR
Patients taking olanzapine added to lithium orValproate experienced sustained symptomatic remission, but not syndromic remission, for longer than those receiving lithium or valproate monotherapy.
A Randomized, Placebo-Controlled 12-Month Trial of Divalproex and Lithium in Treatment of Outpatients With Bipolar I Disorder
TLDR
Divalproex was superior to lithium in longer duration of successful prophylaxis in the study and less deterioration in depressive symptoms and Global Assessment Scale scores, and patients treated with divalproEx had better outcomes than those treated with placebo or lithium on several secondary outcome measures.
The role of novel antipsychotics in bipolar disorders.
  • L. Yatham
  • Psychology
    The Journal of clinical psychiatry
  • 2002
TLDR
Risperidone is shown to be effective for acute mania, both as monotherapy and in combination with mood stabilizers; this agent has also shown efficacy as add-on maintenance therapy in open-label studies as it exhibited both antimanic and antidepressant effects.
An ever-increasing pharmacopoeia for the management of patients with bipolar disorder.
  • C. Nemeroff
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 2000
TLDR
The treatment of patients with bipolar mania is addressed, which remains one of the most difficult challenges facing clinicians, and several anticonvulsant agents are included, as well as conventional and atypical antipsychotic agents.
...
1
2
3
4
5
...